AMAG Pharmaceuticals Inc (AMAG.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2014||Chairman of the Board|
|46||2015||President, Chief Operating Officer|
|55||2015||Chief Executive Officer, Director|
|43||2016||Chief Financial Officer, Senior Vice President - Finance, Treasurer|
|2016||Executive Vice President, Chief Commercial Officer|
- BRIEF-Amag Pharmaceuticals sees Q4 2016 revenue $150 mln to $155 mln
- BRIEF-Amag Pharmaceuticals enters into an agreement to develop and commercialize Rekynda
- BRIEF-Amag Pharma Q3 earnings per share $0.43
- BRIEF-Amag Pharmaceuticals qtrly loss per share $0.02
- BRIEF-Amag Pharmaceuticals says Point72's Steven Cohen reported 5 pct passive stake co - SEC filing